Literature DB >> 10751346

Proliferation in HHV-8-positive primary effusion lymphomas is associated with expression of HHV-8 cyclin but independent of p27(kip1).

A Carbone1, A Gloghini, D Bontempo, P Monini, U Tirelli, R Volpe, P J Browning, G Gaidano.   

Abstract

Primary effusion lymphoma (PEL) develops in immunodeficient patients, selectively localizes to the serous body cavities, and harbors infection by human herpesvirus type-8 (HHV-8), also known as Kaposi's sarcoma-associated herpesvirus. HHV-8 encodes a viral (v)-cyclin homologous to cellular D-type cyclins, a class of positive cell-cycle regulators that are physiologically modulated by the p27(Kip1) cell cycle inhibitor. The aims of the present study were: 1) to establish the expression pattern of p27(Kip1) in PEL; and 2) to address the relationship between p27(Kip1) expression, proliferation index, and expression of cellular cyclin D1 and v-cyclin in PEL. Expression of p27(Kip1) was detected in all (n = 18) PEL samples analyzed by both immunocytochemistry and Western blot. All PELs displayed a high proliferation index as assessed by Ki-67 staining. Expression of cellular cyclin D1 was absent in all PELs tested, which conversely expressed (14 out of 14 samples) v-cyclin by immunocytochemistry and/or Western blot. In contrast to PELs, HHV-8-negative lymphomatous effusions secondary to a tissue-based lymphoma generally failed to express p27(Kip1). Overall, these data show that PELs consistently express p27(Kip1) protein despite the high proliferative rate of the lymphoma clone, suggesting that p27(Kip1) may be unable to drive cell-cycle arrest in PEL cells. The co-existence of p27(Kip1) expression and high proliferative index is a selective feature of PEL among lymphomas involving the serous body cavities, because lymphomatous effusions secondary to a tissue-based lymphoma generally display the inverse relationship between p27(Kip1) positivity and growth fraction observed in normal lymphoid tissues and in most other lymphomas. Expression of p27(Kip1) in PEL associates with expression of HHV-8 v-cyclin, but not of cellular cyclin D1. The fact that HHV-8 v-cyclin is resistant to p27(Kip1)-modulated inhibition, whereas cellular cyclin D1 is sensitive, may explain, at least in part, the co-existence of p27(Kip1) expression and high proliferative index observed in PEL.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10751346      PMCID: PMC1876887          DOI: 10.1016/S0002-9440(10)64991-7

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  31 in total

1.  Formation of p27-CDK complexes during the human mitotic cell cycle.

Authors:  T J Soos; H Kiyokawa; J S Yan; M S Rubin; A Giordano; A DeBlasio; S Bottega; B Wong; J Mendelsohn; A Koff
Journal:  Cell Growth Differ       Date:  1996-02

2.  Cyclin encoded by KS herpesvirus.

Authors:  Y Chang; P S Moore; S J Talbot; C H Boshoff; T Zarkowska; H Paterson; R A Weiss; S Mittnacht
Journal:  Nature       Date:  1996-08-01       Impact factor: 49.962

3.  p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21.

Authors:  H Toyoshima; T Hunter
Journal:  Cell       Date:  1994-07-15       Impact factor: 41.582

4.  Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta.

Authors:  I Reynisdóttir; K Polyak; A Iavarone; J Massagué
Journal:  Genes Dev       Date:  1995-08-01       Impact factor: 11.361

5.  Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas.

Authors:  E Cesarman; Y Chang; P S Moore; J W Said; D M Knowles
Journal:  N Engl J Med       Date:  1995-05-04       Impact factor: 91.245

6.  Establishment and characterization of a primary effusion (body cavity-based) lymphoma cell line (BC-3) harboring kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) in the absence of Epstein-Barr virus.

Authors:  L Arvanitakis; E A Mesri; R G Nador; J W Said; A S Asch; D M Knowles; E Cesarman
Journal:  Blood       Date:  1996-10-01       Impact factor: 22.113

7.  Establishment of AIDS-related lymphoma cell lines from lymphomatous effusions.

Authors:  G Gaidano; K Cechova; Y Chang; P S Moore; D M Knowles; R Dalla-Favera
Journal:  Leukemia       Date:  1996-07       Impact factor: 11.528

8.  Kaposi's sarcoma-associated herpesvirus DNA sequences in AIDS-related and AIDS-unrelated lymphomatous effusions.

Authors:  A Carbone; A Gloghini; E Vaccher; V Zagonel; C Pastore; P Dalla Palma; F Branz; G Saglio; R Volpe; U Tirelli; G Gaidano
Journal:  Br J Haematol       Date:  1996-09       Impact factor: 6.998

9.  In vitro establishment and characterization of two acquired immunodeficiency syndrome-related lymphoma cell lines (BC-1 and BC-2) containing Kaposi's sarcoma-associated herpesvirus-like (KSHV) DNA sequences.

Authors:  E Cesarman; P S Moore; P H Rao; G Inghirami; D M Knowles; Y Chang
Journal:  Blood       Date:  1995-10-01       Impact factor: 22.113

10.  Lytic growth of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in culture.

Authors:  R Renne; W Zhong; B Herndier; M McGrath; N Abbey; D Kedes; D Ganem
Journal:  Nat Med       Date:  1996-03       Impact factor: 53.440

View more
  10 in total

1.  Internal ribosome entry site regulates translation of Kaposi's sarcoma-associated herpesvirus FLICE inhibitory protein.

Authors:  W Low; M Harries; H Ye; M Q Du; C Boshoff; M Collins
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

Review 2.  Molecular virology of Kaposi's sarcoma-associated herpesvirus.

Authors:  P S Moore; Y Chang
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-04-29       Impact factor: 6.237

3.  CpG methylation as a tool to characterize cell-free Kaposi sarcoma herpesvirus DNA.

Authors:  Meir Shamay; Nicholas Hand; M Victor Lemas; Henry B Koon; Susan E Krown; John Wrangle; Prashant Desai; Juan Carlos Ramos; Richard F Ambinder
Journal:  J Infect Dis       Date:  2012-02-22       Impact factor: 5.226

4.  Post-transplant lymphoproliferative disorders: role of viral infection, genetic lesions and antigen stimulation in the pathogenesis of the disease.

Authors:  Daniela Capello; Gianluca Gaidano
Journal:  Mediterr J Hematol Infect Dis       Date:  2009-12-14       Impact factor: 2.576

5.  Expression of cyclin-dependent kinase inhibitor p27(Kip1) in AIDS-related diffuse large-cell lymphomas is associated with Epstein-Barr virus-encoded latent membrane protein 1.

Authors:  Annunziata Gloghini; Gianluca Gaidano; Luigi M Larocca; Francesco Pierconti; Antonella Cingolani; Luigino Dal Maso; Daniela Capello; Silvia Franceschi; Umberto Tirelli; Massimo Libra; Huifeng Niu; Riccardo Dalla-Favera; Antonino Carbone
Journal:  Am J Pathol       Date:  2002-07       Impact factor: 4.307

6.  Disruption of Kaposi's sarcoma-associated herpesvirus latent nuclear antigen leads to abortive episome persistence.

Authors:  Feng-Chun Ye; Fu-Chun Zhou; Seung Min Yoo; Jian-Ping Xie; Philip J Browning; Shou-Jiang Gao
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

Review 7.  Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 and lymphoproliferative disorders.

Authors:  M-Q Du; C M Bacon; P G Isaacson
Journal:  J Clin Pathol       Date:  2007-12       Impact factor: 3.411

Review 8.  Viral latency and its regulation: lessons from the gamma-herpesviruses.

Authors:  Samuel H Speck; Don Ganem
Journal:  Cell Host Microbe       Date:  2010-07-22       Impact factor: 21.023

9.  Body Cavity-Based Lymphoma in a Country with Low Human Immunodeficiency Virus Prevalence: A Series of 17 Cases from the Consortium for Improving Survival of Lymphoma.

Authors:  Junghoon Shin; Young Hyeh Ko; Sung Yong Oh; Dok Hyun Yoon; Jeong-Ok Lee; Jin Seok Kim; Yong Park; Ho Jin Shin; Seok Jin Kim; Jong Ho Won; Sung-Soo Yoon; Won Seog Kim; Youngil Koh
Journal:  Cancer Res Treat       Date:  2019-02-14       Impact factor: 4.679

10.  Primary effusion lymphoma: an untrivial differential diagnosis for ascites.

Authors:  Funda Ceran; Yusuf Aydin; Levent Ozçakar; Unsal Han; Mehmet Yildiz
Journal:  Yonsei Med J       Date:  2009-12-18       Impact factor: 2.759

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.